Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553 - Seite 3
For further information, please contact:
Media Relations | Investor Relations |
Peer Nils Schröder, PhD Head Public Relations & Corporate Communications +41 61 606 1102 media_relations@basilea.com |
Barbara Zink, PhD, MBA Head Corporate Development +41 61 606 1233 investor_relations@basilea.com |
This press release can be downloaded from www.basilea.com.
References
[1] L. R. Molife et al. Phase 1/2a trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase 1 completed. American Society of Clinical Oncology (ASCO) annual meeting 2014, abstract 2562
Lesen Sie auch
[2] F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the spindle assembly checkpoint is required for anticancer activity. American Association for Cancer Research (AACR) annual meeting 2015, abstract 3789
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Globenewswire
--- End of Message ---
Basilea Pharmaceutica AG
Grenzacherstrasse 487 Basel Switzerland
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;